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S328 Poster Session IIchemotherapy for that shift, between the charge nurse and the pa-
tient’s assigned nurse was completed at shift’s beginning. Debrief-
ing between the charge nurse and the patient’s assigned nurse was
completed at shift’s end and consisted of recording the nurse’s re-
sponse to the question, ‘‘Did you have 2 RNs check chemo in the
room?’’
Of the 90 opportunities for chemotherapy administration, all che-
motherapy doses were double-checked at the bedside 100% of the
time after the bedside check implementation. Medication variance
data revealed no patient misidentification chemotherapy errors
were reported for the 3 months prior to and after implementation.
BMT nursing staff consistently changed their practice by imple-
menting a bedside check of chemotherapy. Medication variance
data was inconclusive, as no errors related to patient misidentifica-
tion involving chemotherapy were reported prior to or after the
practice change.
As this practice change continues, we anticipate 0% incidence of
patient misidentification chemotherapy administration-related
errors. This bedside check may offer more opportunities for patients
to inquire about their chemotherapy. Patient satisfaction may
improve if patients see extra care taken to ensure they receive the
intended therapy.469
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Background: Tacrolimus (FK-506) is highly effective in prevent-
ing GVHD in allogeneic HSCT recipients. Traditionally, tacroli-
mus is administered as a 24-hour continuous infusion. This
schedule is logistically difficult. We report our pediatric experi-
ence with twice-daily bolus administration of intravenous (IV)
FK-506.
Methods: From March 2006 until July 2009, 25 pediatric patients
undergoing allogeneic HSCT have received twice daily bolus infu-
sions of iv FK-506 for GVHD prophylaxis. FK-506 was started at
an initial dose of 0.015 mg/kg IV bolus administered as a two hour
infusion beginning on Day -2 or -3 and then given every twelve
hours. Trough drug levels were drawn before the fifth dose and
then monitored twice weekly. The dose was adjusted to maintain
a trough drug level range between 5-15 ng/ml. Bolus iv FK-506 in-
fusions were continued till patients were ready to be transitioned to
the oral route.
Results: Median age of recipients was 10 years (14months –17
years). 16/25 (64%) of patients received matched unrelated grafts
and 9/25 (36%) received matched related donor HSCT Stem cell
sources included bone marrow, peripheral blood and cord blood.
Majority of the patients had also received short course methotrex-
ate or mycophenolate mofetil in combination with iv FK-506 for
GVHD prophylaxis. 10/25 patients had also received anti-thymo-
cyte globulin (ATG).
All bolus infusions of iv-FK-506 were well tolerated, Nephrotox-
icty (defined as 2x baseline creatinine at any time-point during FK-
506 adminitration) was detected in 11/25 (44%) patients. Most of
these patients were receieving other nephrotoxic agents also. Past
studies of continuous infusion FK-506 report nephrotoxicity rates
of 60-80% using the same criteria. No patient required dialysis.
No patient developed HUS/TTP. 12% of patients developed hyper-
tension requiring medical intervention. One patient developed
PRES with seizures and tremors.
Only 1/25 patients developed Grade II GVHD. No Grade III-IV
GVHD was identified.
This was effective GVHD control when compared to historical
results of continous iv FK-506.
Conclusions: Intermittent bolus infusions of FK-506 are easy to ad-
minister and do not correlate with any increased toxicity or risk of
GVHD when compared to past reports of continuos iv administra-
tion.Since access to central venous lines is an important issue inchildren, further studies are warranted to confirm the safety and ef-
ficacy of intermittent Tacrolimus administration.470
BRIDGING THE UNMET NEEDS OF YOUNG ADULTS: CREATING A
SUPPORT GROUP FOR YOUNG ADULT PATIENTS ON THE STEM CELL
TRANSPLANT SERVICE
Rimkus, C., Chiang, K. Barnes-Jewish Hospital, St. Louis, MO
Young adults, ages 18-35, have unique psychosocial needs that
differ from their older counterparts with the same cancer. The
transplant service at a large comprehensive cancer center includes
patients who have all blood related cancers that are being treated
with or without a stem cell transplant. The transplant team appre-
ciates the unique needs of the young adult. Several attempts
aimed at addressing these needs have failed. Our psychosocial ser-
vice developed an outpatient young adult support group that
failed due to poor attendance. Individual support has not been
easily accepted. We even attempted to engage the young adults
in an interactive game/book/DVD program, with minimal success.
Over the past year, the inpatient staff started noticing the young
adult patients gathering in common spaces, even going to each
other rooms to gain the support from other patients with like dis-
eases and concerns. Given that the average length of stay for the
blood cancer patient is three weeks and that the young adults have
been interactive in the already established discharge planning
class, the staff felt that an inpatient support group was a viable
untapped option. The staff asked the young adults if they felt
a young adult support group that was held on the unit would
be helpful to them. The twenty-five to thirty-five year olds were
very interested in having their needs addressed and were inter-
ested in gaining the support of others with like concerns. The pa-
tients younger than twenty-five were non-committal. Partnering
with the psycho-oncology service, the clinical nurse specialist de-
veloped a young adult support group. A proposal was developed
and presented to the cancer center’s patient programming com-
mittee as well as the director of oncology services. Once accepted,
the proposal was presented to the nursing staff. Group ground
rules have been established to address the potential anger and
emotion that can be evoked from this population. Marketing for
the program will include having the unit staff and chaplain pro-
mote attendance. The goal of this poster is to outline the steps
included in developing a support group, identifying the challenges
as well as rewards. The plan is to start this inpatient young adult
support group in November and collect data for 3 months as to
attendance, feedback from patients and then eventually to see if
this leads to opportunities to help this psychologically under-
served population.471
CHEMOTHERAPY DOSE ADJUSTMENT FOR OBESITY IN HEMATOPOIETIC
STEM CELL TRANSPLANTATION
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More than 50 million adults in the US are overweight and al-
most 70% qualify for the diagnosis of obesity. In 2010, 1.6 million
new cases of cancer are expected to be diagnosed. That number is
expected to increase by 45% in the next 20 years. Recent studies
have shown that obesity is associated with an increased risk of cer-
tain types of cancer. A large number of patients with cancer will
receive chemotherapy as treatment for their disease. Although re-
nal, cardiac and liver function play a role in dose adjustment of
chemotherapy, patient and drug specific factors (i.e. obesity,
drug’s protein binding, its lipophilicity) must also be considered.
The level of excess body weight that requires dose adjustment re-
mains controversial. Myeloablative hematopoietic stem cell trans-
plantation (HSCT) is based on the use of high doses of
chemotherapy such as busulfan. High serum concentrations of
such drugs have been associated with the development of life-
threatening complications like veno-occlusive disease. For this
reason, many practitioners empirically adjust chemotherapy dosing
in obese patients by using adjusted weight or capping body surface
